08:32 AM EDT, 06/24/2024 (MT Newswires) -- GSK (GSK) said in a regulatory filing Monday that Japan's Ministry of Health, Labour and Welfare has approved Omjjara for the treatment of myelofibrosis, a rare blood cancer.

The approval was based on data from the Momentum and Simplify-1 pivotal phase 3 trials, GSK said in a 6-K filing with the US Securities and Exchange Commission.

GSK shares were up 0.5% in recent US premarket trading.

Price: 40.69, Change: +0.21, Percent Change: +0.52